Lla, Foà (Sapienza): “Significantly prolonged survival for those who received blinatumomab”

“The Phase III E1910 clinical trial demonstrates that survival is significantly prolonged in patients who received the bispecific antibody blinatumomab compared to what is called standard of care in English.” This was explained by Robin Foà, professor emeritus of Hematology at the Sapienza University of Rome, on the sidelines of the event with which Amgen illustrated the results of the Phase III E1910 clinical study which demonstrate how the introduction of the bispecific monoclonal antibody blinatumomab in First line treatment significantly increases the overall survival of patients with newly diagnosed Ph- B lymphocyte acute lymphoblastic leukemia (ALL).